Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Sznol

Showing results (11-20 of 65) with videos related to

Pageof 7
Sort By:
Oncology (Williston Park, N.Y.)|June 1, 1994
Clinical applications of IL-2M Sznol, D R Parkinson
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1992
Adoptive cellular therapyM Sznol, W J Urba
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1994
Adoptive immunotherapyM Sznol, W J Urba
Seminars in Liver Disease|August 1, 1987
Hepatic toxicity of drugs used for hematologic neoplasiaM Sznol, T Ohnuma, J F Holland
Oncology (Williston Park, N.Y.)|October 1, 1995
Clinical trials referral resource. Tumor vaccine clinical trialsB D Cheson, M Sznol, P H Phillips
Seminars in Oncology|October 1, 1993
Biologic therapies for low-grade lymphomasD R Parkinson, M Sznol, B D Cheson
Oncology (Williston Park, N.Y.)|January 1, 1997
Clinical Trials Referral Resource. Trials using tumor vaccinesB D Cheson, P H Phillips, M Sznol
Oncology (Williston Park, N.Y.)|June 1, 1993
Clinical trials referral resource. NCI-sponsored trials of interleukin-6 (IL-6)B D Cheson, C L Carter, M Sznol
Important Advances in Oncology|January 1, 1990
5-Fluorouracil plus levamisole: effective adjuvant treatment for colon cancerJ M Hamilton, M Sznol, M A Friedman
The Cancer Journal From Scientific American|February 24, 2000
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival updateM B Atkins, L Kunkel, M Sznol, et al.
Pageof 7

Showing results (11-20 of 65) with videos related to

Sort By:
Pageof 7
Oncology (Williston Park, N.Y.)|June 1, 1994
Clinical applications of IL-2M Sznol, D R Parkinson
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1992
Adoptive cellular therapyM Sznol, W J Urba
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1994
Adoptive immunotherapyM Sznol, W J Urba
Seminars in Liver Disease|August 1, 1987
Hepatic toxicity of drugs used for hematologic neoplasiaM Sznol, T Ohnuma, J F Holland
Oncology (Williston Park, N.Y.)|October 1, 1995
Clinical trials referral resource. Tumor vaccine clinical trialsB D Cheson, M Sznol, P H Phillips
Seminars in Oncology|October 1, 1993
Biologic therapies for low-grade lymphomasD R Parkinson, M Sznol, B D Cheson
Oncology (Williston Park, N.Y.)|January 1, 1997
Clinical Trials Referral Resource. Trials using tumor vaccinesB D Cheson, P H Phillips, M Sznol
Oncology (Williston Park, N.Y.)|June 1, 1993
Clinical trials referral resource. NCI-sponsored trials of interleukin-6 (IL-6)B D Cheson, C L Carter, M Sznol
Important Advances in Oncology|January 1, 1990
5-Fluorouracil plus levamisole: effective adjuvant treatment for colon cancerJ M Hamilton, M Sznol, M A Friedman
The Cancer Journal From Scientific American|February 24, 2000
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival updateM B Atkins, L Kunkel, M Sznol, et al.
Pageof 7